Bosh sahifaMRCK34 • BVMF
add
Merck BDR
Yopilish kursi
76,46 R$
Kunlik diapazon
75,59 R$ - 78,87 R$
Yillik diapazon
61,00 R$ - 94,00 R$
Bozor kapitalizatsiyasi
260,86 mlrd USD
Oʻrtacha hajm
5,68 ming
Yangiliklarda
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Daromad | 16,66 mlrd | 4,35% |
Joriy xarajat | 8,40 mlrd | 48,81% |
Sof foyda | 3,16 mlrd | -33,47% |
Sof foyda marjasi | 18,95 | -36,26% |
Har bir ulushga tushum | 1,57 | -26,29% |
EBITDA | 5,51 mlrd | -21,97% |
Amaldagi soliq stavkasi | 22,71% | — |
Balans
Jami aktivlari
Jami passivlari
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Naqd pul va qisqa investitsiyalar | 14,59 mlrd | 66,34% |
Jami aktivlari | 117,53 mlrd | 10,12% |
Jami passivlari | 72,97 mlrd | 11,53% |
Umumiy kapital | 44,56 mlrd | — |
Tarqatilgan aksiyalar | 2,53 mlrd | — |
Narxi/balansdagi bahosi | 4,35 | — |
Aktivlardan daromad | 9,48% | — |
Kapitaldan daromad | 13,29% | — |
Pul aylanmasi
Naqd pulning sof oʻzgarishi
| (USD) | sen, 2024info | Y/Y qiyosi |
|---|---|---|
Sof foyda | 3,16 mlrd | -33,47% |
Operatsiyalardan naqd pul | 9,29 mlrd | 20,40% |
Sarmoyadan naqd pul | -3,84 mlrd | -1 051,20% |
Moliyadan naqd pul | -2,42 mlrd | 43,20% |
Naqd pulning sof oʻzgarishi | 3,32 mlrd | 12,11% |
Boʻsh pul | 7,42 mlrd | 28,97% |
Haqida
Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of which it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada. It is one of the largest pharmaceutical companies in the world, generally ranking in the global top five by revenue.
Merck & Co. was originally established as the American affiliate of Merck Group in 1891. Merck develops and produces medicines, vaccines, biologic therapies and animal health products. It has several blockbuster products, including cancer immunotherapy, anti-diabetic medications, and vaccines for HPV and chickenpox, each generating significant revenue as of 2020.
The company is ranked 71st on the 2022 Fortune 500 and 87th on the 2022 Forbes Global 2000, both based on 2021 revenues. In 2023, the company’s seat in Forbes Global 2000 was 73. Wikipedia
Tashkil etilgan
1-yan, 1891
Sayt
Xodimlar soni
71 000
